drugset / Trial / NCT04387630

Neoadjuvant Chemotherapy With or Without Metformin in Early Breast Cancer.

NCT04387630

Phase 2/3 Unknown 120 enrolled Mansoura University
RandomizedParallel-groupOpen-labelTreatment

Summary

Metformin is a widely used anti-diabetic drug. Several studies have pointed out a potentially beneficial effect of metformin therapy in diabetic cancer patients. Several studies are investigating the anti-tumor effect of metformin in early breast cancer. However, the enhancing effect of metformin on anti-tumor immunity has only been demonstrated in animal models. This study examines the immune effect of metformin in breast cancer patients treated with preoperative chemotherapy.

Timeline

Start
2020-06-05
Primary completion
2022-06-05
Completion
2023-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule 2550 mg Oral

Indications